Jetblack Corp. (OTC: JTBK) “The Company” “JTBK” provided more in-depth details recently on their first of its kind wellness product in formulation. JTBK has been formulating a product that helps flush or cleanse the endocannabinoid system and CB1 and CB2 receptors which may make marijuana more effective. Jetblack Corp.(JTBK) has started to seek out distribution partners for its endocannabinoid product in development. The company is seeking distributors with a broad network to partner with on this product. ‘We have received wonderful feedback since we released details about the “wellness” product,’ stated Daniel A. Goldin CEO of Jetblack Corp. “We would like to get distributors on board, so that once the final touches on formulation are complete. We will have distribution in place, ready to go to market,” explained the CEO.
The more a person smokes or ingests marijuana, there becomes a diminishing rate of effectiveness compared to an individual who consumes cannabis less regularly. If an individual is a regular consumer of marijuana, the effects are much milder and less effective than someone who ingests less regularly. Often heavy users complain about never getting high, barely feeling anything, or needing concentrates to get the desired effects. At a certain point for the regular user, even the concentrates will have little effect. In comparison to a user who consumes cannabis less regularly, they will feel much greater effects of the cannabis once consumed. A regular user often states, “I wish I could feel the effects like I used to when I first started.”
JTBKs product helps flush the endocannabinoid system and receptors so that a regular user can use less marijuana and be acutely more effective for the goals they would like to achieve. Potentially this will save the consumer money by using less marijuana products, have greater effectiveness for their desired effect, along with less unwanted side effects that marijuana gives by consuming less cannabis. In addition, a user will have less need to be constantly searching for different potent strains or strains with the highest thc content, so that they can feel the effects. A marijuana medical patient may also benefit greatly from this product by making marijuana much more effective for relief of their conditions.
For someone that is looking to stop consuming cannabis for whatever reason, this product may also help to clear your system for weening off of the cannabis. Sometimes heavy users will have some unwanted side effects from suddenly stopping consumption. Some individuals may suffer a loss of appetite from suddenly stopping consumption. Along with, irritability and restless sleep to name a few. Often a regular user who stops consumption for 2 weeks may still up to 500 nanograms or more in their system. Sometimes a regular user will need up to 60 days to clear their system completely. Our product may help clean out the system much faster, which will give less side effects to the individual in the weening process.
In addition, JTBK has a new company website which can be found at JetblackCorp.com. The website details the company’s overall vision for creating unique products that may benefit society and/or the environment. The company plans to spend small amounts of capital developing and distributing multiple products across a variety of sectors, which will distribute the risk of capital investment across multiple product lines. Being that the focus is on products that benefit people or the planet, we feel it gives investors the opportunity to put their capital to work for a good cause and hopefully be rewarded with upside, explained CEO Daniel A. Goldin.
Inquiries regarding becoming a distributor or wholesaler for the endocannabinoid product should be directed to email@example.com or by calling 1-888-611-5825 and leaving a detailed message.
More information about Jetblack Corp.can be found at theirwebsitewww.Jetblackcorp.com and their twitter handle @jetblackcorp.
Inquiries regarding making an investment or financing the company may be directed to1-888-611-5825 by leaving a detailed message. Interested parties may also send an email to firstname.lastname@example.org.
This press release contains forward-looking statements. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believe,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties include market risks associated with our business, the inability to raise enough capital to complete our business, economic conditions and increasing competition. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company’s control which could, and likely will materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy and liquidity. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The loss of key employees would be detrimental to the company’s success. Currently, the company is considered a penny stock, which means the spreads can be very far apart, sometimes illiquid, and investors may not be able to sell when they want or for the price paid. In some circumstances, the investor may lose all their investment.
Emilia S. Olvera